White House Moves To Expand U.S. Research Into Ibogaine for PTSD and Addiction

Federal officials are preparing an executive order to encourage expanded U.S. research into ibogaine, a psychedelic compound used abroad to treat post-traumatic stress disorder, addiction and other conditions, sources told CBS News.

The White House draft would signal an administration willingness to facilitate and support research into ibogaine while leaving its current legal classification unchanged. Officials say the drug would remain a Schedule I substance under federal law, meaning it is still considered to have no accepted medical use and a high potential for abuse.

What the Executive Order Would Do

According to multiple sources, the order is intended to open the door to federal funding and coordination for clinical trials focused on ibogaine’s potential to treat PTSD and traumatic brain injuries, with particular interest in benefits for veterans. Administration officials described the research as early-stage and said the goal is to determine whether ibogaine is an effective treatment or merely unproven hype.

Two sources told CBS News that President Trump intends to sign the executive order as soon as this week. White House spokespeople did not immediately comment.

Existing Evidence and Ongoing Research

Most existing studies of ibogaine are small observational studies or open-label trials. Only one double-blind, placebo-controlled randomized clinical trial has been completed, and larger, more definitive trials are only now beginning to get underway.

Researchers say ibogaine shows promise — particularly for opioid dependence and certain trauma-related conditions — but emphasize that robust, large-scale clinical trials are required to evaluate safety and effectiveness.

Safety Concerns

The most serious concern is cardiac risk. Ibogaine can cause dangerous heart rhythm disturbances that have in some cases been fatal. A 2023 review of 24 studies involving 705 people found that while ibogaine appeared to reduce withdrawal symptoms and craving, heart toxicity and the risk of death were 'worrying.' The review identified at least 27 deaths associated with ibogaine use.

A small Stanford Medicine study published last July involved 30 veterans who received ibogaine combined with intravenous magnesium as a cardiac protective measure and reported no serious cardiac events. That trial reported reductions in PTSD, anxiety and depression in those participants, but with only 30 people and no placebo arm the results are far too limited to draw definitive safety or efficacy conclusions.

Regulatory and Practical Issues

Because ibogaine is illegal in the United States, many Americans travel to overseas clinics—often in Mexico or the Caribbean—to receive treatment. Those clinics typically operate without U.S. regulatory oversight: there is no standardized cardiac screening, no required monitoring protocol and no obligation to report adverse events to U.S. authorities.

It remains unclear how the federal government would practically facilitate further research; officials said strategies were still being developed in internal discussions. Separately, Texas has recently approved $50 million in state funding to study ibogaine, indicating growing domestic interest in exploring the compound.

Bottom line: The planned executive order would not reclassify ibogaine but could unlock federal resources for clinical trials. Early findings are mixed and safety concerns — particularly cardiac toxicity and reports of deaths — mean that rigorous research is needed before the drug can be considered safe or effective for widespread medical use.